225Ac-DOTATOC is one alpha-labeled analogue of 90Y- and 177Lu-DOTATOC (Solucin).
This alpha-labeled analogue of a radiolabeled somatostatin was developed to be used in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) refractory to previous treatment with 90Y- or 177Lu-DOTATOC.
A clinical trial in 39 patients was reported in 2015. Additional preclinical data were reported recently. Purpose of this study was to evaluate the absorbed dose in vital organs and the risk linked to the contaminant 227Ac.
Target/Mechanism: Somatostatin receptors
Leading Emitter: alpha particle (α)